High Rate of Non-Eligibility: Methodological Factors Impacting on Recruitment for a Multicentre, Double-Blind Study of Paediatric Patients with Major Depressive Disorder

Abstract

Introduction:

This report describes difficulties encountered when attempting to recruit children and adolescents with major depression for a recent international double-blind, placebo-controlled trial (www.clinicaltrials.gov Nr. NCT00849901).

Methods:

Over a 14-month period, children and adolescents with depressive symptoms were pre-screened for their eligibility for inclusion.

Results:

85 patients (age 7–17 years) were considered. Of these, only one was enrolled. The main reasons for non-eligibility were: failure to meet the baseline severity criterion on the primary outcome scale (Clinical Global Impression – Severity; 32.1% of the patients); requirement for immediate hospitalisation (15.4%); or the presence of an exclusionary comorbid psychiatric disorder (19.1%).

Discussion:

The recruitment of paediatric patients with major depression was primarily limited by various inclusion and exclusion criteria. Slow recruitment of small patient samples may impact strongly on the representativeness and generalisability of research findings, and thus on analyses in evidence-based medicine and on the development and recommendations of treatment guidelines. This may impact in turn on the feasibility of the clinical development and registration process of new compounds in paediatric psychopharmacology and beyond.

Key words

recruitment - eligibility - major depression - paediatric patients

• References

• 1 Lehmann B. Regulation (EC) No 1901/2006 on medicinal products for paediatric use & clinical research in vulnerable populations. Child Adolesc Psychiatry Ment Health 2008; 2: 37
• 2 Gruttadaro DE, Miller JE. NAM1 Policy Research Institute Task Force Report Children and Psychotropic Medications. (available on NAMI’s web site at www.nami.org).www.fda.gov/ohrms/dockets/dailys/04/aug04/083104/04n-0330-ts00001-02-vol1.pdf
• 3 Publication European Commission. Discussions in the Council are progressing well and the proposed Regulation on medicinal products for paediatric use will be discussed at the Health Council of 9 December 2005. [ http:// ec.europa.eu/ enterprise/ pharmaceuticals/ paediatrics/ medchild_key_en.htm ]
• 4 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (1) [ http://europa.eu/eurlex/pri/en/oj/dat/2001/l_121/l_12120010501en00340044.pdf ]
• 5 Plueck J, Freund-Braier I, Hautmann C et al. Recruitment in an indicated prevention program for externalizing behavior – parental participation decisions. Child Adolesc Psychiatry Ment Health 2010; 4: 15
• 6 Walson PD. Patient recruitment: US perspective. Pediatrics. 1999. 104. 619-622
• 7 Haberfellner EM. Recruitment of depressive patients for a controlled clinical trial in a psychiatric practice. Pharmacopsychiatry 2000; 33: 142-144
• 8 Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry 1996; 57: 572-575
• 9 Greil W, Ludwig-Mayerhofer W, Steller B et al. The recruitment process for a multicenter study on the long-term prophylactic treatment of affective disorders. J Affect Disord 1993; 28: 257-265
• 10 Bowen J, Hirsch S. Recruitment rates and factors affecting recruitments for a clinical trial of a putative anti-psychotic agent in the treatment of acute schizophrenia. Hum Psychopharmacol 1992; 7: 337-341
• 11 Meyer zur Capellen K, Schmauß M, Messer T. Determinanten für den Ein- und Ausschluss von schizophrenen Patienten bei Phase III- und IV-Studien an einer psychiatrisch-psychotherapeutischen Versorgungsklinik. Available at: edoc.ub.uni-muenchen.de/10477/1/Meyer_zur_Capellen_Kathrin.pdf
• 12 Hewell K, Hoste R, le Grande D et al. Recruitment for an adolescent bulimia nervosa treatment study. Int J Eating Disord 2006; 39: 594-597
• 13 Emslie GJ, Ryan ND, Wagner KD et al. Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. J Clin Psychiatry 2005; 66 (Suppl. 07) 14-20
• 14 Glickman SW, Anstrom KJ, Lin L et al. Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. Ann Emerg Med 2008; 51: 775-780
• 15 Findling RL, Robb A, Nyilas M et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165: 1432-1441
• 16 Findling RL, Nyilas M, Forbes RA et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70: 1441-1451
• 17 Kryzhanovskaya L, Schulz SC, McDougle C et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 60-70
• 18 Haas M, Unis AS, Armenteros J et al. 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19: 611-621
• 19 Dittmann RW, Schacht A, Helsberg K et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol 2011; 21: 97-110
• 20 Michelson D, Faries D, Wernicke J et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: E83
• 21 Michelson D, Buitelaar JK, Danckaerts M et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 896-904
• 22 Emslie GJ, Heiligenstein JH, Hoog SL et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1397-1405
• 23 Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolescent Psychiatry 2002; 41: 1205-1215
• 24 LeBlanc JC, Binder CE, Armenteros JL et al. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. Int Clin Psychopharmacol 2005; 20: 275-283
• 25 Reyes M, Buitelaar J, Toren P et al. randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402-410
• 26 Bain J. Treatment of acute otitis media: are children entered into trials representative?. Br J Gen Pract 2001; 51: 132-133
• 27 Shilling V, Williamson PR, Hickey H et al. Processes in recruitment to randomized controlled trials of medicine for children (RECRUIT): a qualitative study. Hlth Technol Assess 2011; 15: 15
• 28 Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 2007; 4: 28-37
• 29 Posner K, Brown GK, Stanley B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266-1277